Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer

Anti-Cancer Drugs

Volumn 17, Issue 3, 2006, Pages 337-343

  Petit, Thierry ^a   Benider, Abdellatif ^b   Yovine, Alejandro ^c   Bougnoux, Philippe ^d   Spaeth, Dominique ^e   Maindrault Goebel, Frédérique ^f   Serin, Daniel ^g   Tigaud, Jean Dominique ^h   Eymard, Jean Christophe ⁱ   Simon, Hélène ^j   Bertaux, Brigitte ^k   Brienza, Silvano ^k   Cvitkovic, Esteban ^c  

^a CENTRE PAUL STRAUSS   (France)

^b CHU Averroes   (Morocco)

^c CAC   (France)

^d CHU BRETONNEAU   (France)

^e CENTRE ALEXIS VAUTRIN   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g INSTITUT SAINTE CATHERINE   (France)

^h EDOUARD HERRIOT HOSPITAL   (France)

ⁱ INSTITUT JEAN GODINOT   (France)

^j BREST UNIVERSITY HOSPITAL   (France)

^k Debioclinic ^*  (France)

more..

Author keywords

Anthracycline; Breast cancer; Oxaliplatin; Pre treated; Taxane; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; FLUOROURACIL; NAVELBINE; OXALIPLATIN; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; LIVER METASTASIS; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; TAXOIDS; VINBLASTINE;

EID: 33646095183     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200603000-00013     Document Type: Article

References (40)

1. American Cancer Society. Cancer facts and figures. Washington, DC: ACS; 2004.
2. Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 1999; 56:67-78.
3. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky E, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21:588-592.
4. Livingston R, Ellis G, Gralow J, Williams MA, White R, McGuirt C, et al. Dose-intensive vinorelbine with current granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997; 15:1395-400.
5. Spielmann M, Martin M, Namer M, duBois A, Unger C, Dodwell DJ. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin Breast Cancer 2001; 2:47-51.
6. Fumoleau P, Largiller R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated meastatic breast cancer. Eur J Cancer 2004; 40:536-542.
7. Reichardt P, von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14:1227-1233.
8. Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, et al. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol 2002; 20:2551-2558.
9. Razis E, Kosmidis P, Aravantinos G, Bakoyiannis C, Janinis J, Timotheadou H, et al. Second line chemotherapy with 5-fluorouracil and vinorelbine in anthracycline and taxane pretreated patients with metastatic breast cancer. Cancer Invest 2004; 22:10-15.
10. Frasci G, D'Aiuto G, Comella P, Thomas R, Capasso I, Botti G, et al. A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients. Oncology (Huntingt) 2002; 62:25-32.
11. Vassilomanolakis M, Koumakis G, Demiri M, Missitzis J, Barbounis V, Efremidis AP. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment. Cancer Invest 2003; 21:497-504.
12. Weber B, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995; 13:2722-2730.
13. Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13:2567-2574.
14. Kornek G, Ullrich-Pur H, Penz M, Haider K, Kwasny W, Depisch D, et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001; 19:621-627.
15. Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, et al. Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 2000; 18:3370-377.
16. Dieras V, Extra JM, Bellissant E, Espie M, Morvan F, Pierga JY, et al. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 1996; 14:3097-3104.
17. Woynarowski J, Faivre S, Herzig M, Arnett B, Chapman W, Trevino AV, et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000; 58:920-927.
18. Raymond E, Faivre S, Woynarowski J, Chaney S. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25:4-12.
19. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52:1855-1865.
20. MacKay H, Cameron D, Rawhilly D, McKean M, Paul J, Kaye S, et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease free survival [abstract]. Proc Am Assoc Cancer Res 1999; 40:492.
21. Garufi C, Nistico C, Brienza S, Vaccaro A, D'Ottavio A, Zappala A, et al. Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol 2001; 12:1791-1782.
22. Raymond E, Chaney S, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9:1053-1071.
23. Ashizawa T, Asada M, Kobayashi E, Okabe M, Gomi K, Hirata T. Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice. Anticancer Drugs 1993; 4:577-583.
24. Guastalla JP, Delozier T, Chollet P, Mousseau M, Delva R, Vannetzel JM, et al. Phase II study of a 5-fluorouracil (5-FU), oxaliplatin (OXA) and navelbine (NVB) combination (FON) in patients (pts) with advanced/metastatic breast cancer (AMBC) previously treated with anthracyclines (A) and Taxanes (T) [abstract]. Proc Am Soc Clin Oncol 2002; 21 (2): 58b.
25. Monnet I, de Cremoux CH, Soulie P, Saltiel-Voisin S, Bekradda M, Saltiel JC, et al. Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Ann Oncol 2002; 13:103-107.
26. Robieux I, Sorio R, Borsatti E, Cannizzaro R, Vitali V, Aita P, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996; 59:32-40.
27. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10.
28. Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzhaki M, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69:893-900.
29. Therasse P, Arbuck SG, Eisenhauer E. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
30. Piccart M, Raymond E, Aapro M, Eisenhauer EA, Cvitkovic E. Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Eur J Cancer 1995; 31A:S1-S10.
31. Pivot X, Asmar L, Buzdar A, Valero V, Hortobagyi G. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 2000; 82:529-534.
32. Ravdin P. Anthracycline resistance in breast cancer: clinical applications of current knowledge. Eur J Cancer 2002; 31A:S11-S14.
33. Kalbakis K, Kourousis C, Kakolyris S, Mavroudis D, Souglakos J, Agelaki S, et al. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes. Br J Cancer 2001; 85:798-802.
34. Udom DI, Vigushin DM, Linardou H, Graham H, Palmieri C, Coombes R. Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Eur J Cancer 2000; 36:177-182.
35. Campone M, Vorobiof D, Cotes-Funes H, Verrill MW, Khoo K, Slabber C, et al. Preliminary results of a phase II study of intravenous vinflunine as second line therapy in patients with metastatic breast cancer after anthracycline-taxane based regimen failure [abstract]. Breast Cancer Res Treat 2003; 82: S85.
36. Girre V, Dalenc F, Laurence V, Jouve M, Dieras V, Pierga JY, et al. Vinorelbine-5-fluorouracil combination as second line chemotherapy in metastatic breast cancer (MBC) after anthracycline-taxanes combination (AT) [abstract]. Ann Oncol 2000; 11:24.
37. Wist E, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 2004; 43:186-189.
38. Miller KD, Chap LI, Holmes F, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799.
39. Delaloge S, Tubiana-Hulin M, Wardley A, Del Mastro L, Santoro A, Zambelli A, et al. A multistep randomized phase II/III trial comparing oxaliplatin (OXA) + 5fluorouracil (FU) to vinorelbine (VIN) + FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): Final results [abstract]. Proc Am Soc Clin Oncol 2004; 23:41.
40. Pienkowski T, Jagiello-Gruszfeld A. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines. Int J Clin Pharmacol Res 2001; 21:111-117.